A Phase 2 interventional study of V160 and Placebo in Cytomegalovirus (CMV) Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 95 sites in 7 countries. Open to female participants aged 16 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age. Participants received blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and were followed to approximately Month 24. The primary hypothesis of the study was that administration of a 3-dose regimen of V160 will reduce the incidence of primary CMV infection compared to placebo.
2,097 studies on the registry are indexed under Infections; 361 are open to participants now.
This study's enrollment of 2,200 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
Biological: V160
Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.
Biological: V160 · Drug: Placebo
Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.
Drug: Placebo
V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
Also known as: Human cytomegalovirus vaccine
Saline solution administered as a 0.5 mL IM injection
Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)
Cytomegalovirus infection (CMVi) was defined as the detection of wild-type cytomegalovirus (CMV) (non vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 3-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 3-dose regimen group compared to the placebo group was assessed.
Time frame: 4 weeks post last vaccination (Month 7) up to ~Month 24
Number of Participants With Solicited Injection-site Adverse Events
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and pain.
Time frame: Up to 5 days after each vaccination
Number of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, joint pain/arthralgia, muscle pain/myalgia, and headache.
Time frame: Up to 14 days after each vaccination
Number of Participants With Vaccine-related Serious Adverse Events
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V160 or placebo, the number of participants with vaccine-related serious adverse events was assessed.
Time frame: Up to 14 days after each vaccination
Number of Participants Who Became Infected With Wild-Type CMV Infection Starting at 4 Weeks Post Last Dose (V160 2-dose Regimen Group and Placebo Group)
CMVi is defined as detection of wild-type CMV (non-vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 2-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 2-dose regimen group compared to the placebo group was assessed.
Time frame: 4 weeks post last vaccination (Month 7) up to ~Month 24
| Milestone | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo |
|---|---|---|---|
| Started | 733 | 733 | 734 |
| Treatment 1 | 729 | 729 | 733 |
| Treatment 2 | 680 | 680 | 679 |
| Treatment 3 | 614 | 631 | 622 |
| Completed | 614 | 631 | 622 |
| Not completed | 119 | 102 | 112 |
| Withdrew: Withdrawal by subject | 46 | 46 | 52 |
| Withdrew: Adverse event | 8 | 7 | 0 |
| Withdrew: Lost to follow-up | 41 | 24 | 39 |
| Withdrew: Non-compliance with study drug | 2 | 2 | 0 |
| Withdrew: Physician decision | 5 | 2 | 3 |
| Withdrew: Pregnancy | 10 | 12 | 12 |
| Withdrew: Protocol deviation | 2 | 3 | 3 |
| Withdrew: Withdrawal by parent/guardian | 1 | 2 | 2 |
| Withdrew: Randomized but not treated | 4 | 4 | 1 |
Cytomegalovirus infection (CMVi) was defined as the detection of wild-type cytomegalovirus (CMV) (non vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 3-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 3-dose regimen group compared to the placebo group was assessed.
| Participants | V160 3-Dose Regimen | Placebo |
|---|---|---|
| Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group) | 14 | 24 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and pain.
| Participants | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo |
|---|---|---|---|
| Number of Participants With Solicited Injection-site Adverse Events | 683 | 668 | 249 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, joint pain/arthralgia, muscle pain/myalgia, and headache.
| Participants | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo |
|---|---|---|---|
| Number of Participants With Solicited Systemic AEs | 621 | 633 | 508 |
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V160 or placebo, the number of participants with vaccine-related serious adverse events was assessed.
| Participants | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo |
|---|---|---|---|
| Number of Participants With Vaccine-related Serious Adverse Events | 0 | 0 | 0 |
CMVi is defined as detection of wild-type CMV (non-vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 2-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 2-dose regimen group compared to the placebo group was assessed.
| Participants | V160 2-Dose Regimen | Placebo |
|---|---|---|
| Number of Participants Who Became Infected With Wild-Type CMV Infection Starting at 4 Weeks Post Last Dose (V160 2-dose Regimen Group and Placebo Group) | 31 | 24 |
Collected over All-cause mortality and serious adverse events: Up to ~Month 24; Non-serious adverse events: Up to 14 days following any vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V160 3-Dose Group | 0/733 (0%) | 22/728 (3%) | 697/728 (95.7%) |
| V160 2-Dose Group | 0/733 (0%) | 29/729 (4%) | 700/729 (96%) |
| Placebo Group | 0/734 (0%) | 26/732 (3.6%) | 557/732 (76.1%) |
| Event | V160 3-Dose Group | V160 2-Dose Group | Placebo Group |
|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/728 | 6/729 | 7/732 |
| DepressionPsychiatric disorders | 2/728 | 0/729 | 1/732 |
| CholelithiasisHepatobiliary disorders | 0/728 | 2/729 | 0/732 |
| PneumoniaInfections and infestations | 1/728 | 2/729 | 0/732 |
| Urinary tract infectionInfections and infestations | 0/728 | 2/729 | 0/732 |
| Ankle fractureInjury, poisoning and procedural complications | 0/728 | 2/729 | 1/732 |
| Anembryonic gestationPregnancy, puerperium and perinatal conditions | 0/728 | 0/729 | 2/732 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/728 | 0/729 | 2/732 |
| Abdominal pain lowerGastrointestinal disorders | 1/728 | 1/729 | 0/732 |
| Oesophageal ulcerGastrointestinal disorders | 1/728 | 0/729 | 0/732 |
| Event | V160 3-Dose Group | V160 2-Dose Group | Placebo Group |
|---|---|---|---|
| Injection site painGeneral disorders | 680/728 | 664/729 | 239/732 |
| FatigueGeneral disorders | 457/728 | 461/729 | 357/732 |
| MyalgiaMusculoskeletal and connective tissue disorders | 455/728 | 424/729 | 200/732 |
| HeadacheNervous system disorders | 434/728 | 450/729 | 368/732 |
| Injection site erythemaGeneral disorders | 254/728 | 208/729 | 30/732 |
| Injection site swellingGeneral disorders | 248/728 | 233/729 | 21/732 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 162/728 | 162/729 | 76/732 |
| PyrexiaGeneral disorders | 75/728 | 90/729 | 27/732 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 62/728 | 65/729 | 69/732 |
| NauseaGastrointestinal disorders | 45/728 | 55/729 | 46/732 |
| Age, Continuous(Years) | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| Mean | 26.0 ± 5.0 | 26.1 ± 4.9 | 25.9 ± 4.9 | 26.0 ± 4.9 |
| Sex: Female, Male(Participants) | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| Female | 733 | 733 | 734 | 2200 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 144 | 145 | 143 | 432 |
| Not Hispanic or Latino | 588 | 585 | 587 | 1760 |
| Unknown or Not Reported | 1 | 3 | 4 | 8 |
| Race (NIH/OMB)(Participants) | V160 3-Dose Regimen | V160 2-Dose Regimen | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 4 | 5 |
| Asian | 6 | 7 | 6 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 47 | 49 | 43 | 139 |
| White | 657 | 652 | 665 | 1974 |
| More than one race | 23 | 23 | 16 | 62 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Apr 2018 to primary completion in Oct 2020, 30 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 19. This study's 30 months is above that.
Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: V160